We have combined a proprietary database of single cell genomic data with an AI/ML-powered computational platform that allows us to compare the normal healthy cell states of development to the dysfunctional cell states found in a range of human diseases. This mapping allows us to define the drivers of the diseased cell states and target these for therapeutic interventions.
We have assembled a team with deep expertise in biology, medicinal chemistry, and computational science who work closely with leading physician-scientists.
At the center of everything we do are the patients. As pioneers in cell state drug development, we aim to offer patients longer, higher quality lives.
We have fostered a culture that encourages our team to be curious, to think strategically and creatively, and to push the limits of science. We honor diversity and individuality, and are united by a single commitment to serve the patients and families who need new treatments.
Auron Therapeutics Announces Poster Presentation at 2025 AACR Annual Meeting
Newton, MA, March 26, 2025 – Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced that the Company will present updated preclinical data from its lead program, AUTX-703, during a poster session at the American Association for Cancer Research (AACR) Annual Meeting from April 25-30, 2025 in Chicago, IL.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.
